In line with this, high expression of PD-1 on circulating CD4+ T cells was associated with shorter progression-free and overall survival in patients with advanced NSCLC [78, 79] and identified patients who responded poorly to anti-PD-L1 therapy [79]. Here, CD4 is linked to non-small cell lung carcinoma.